Docoh
Loading...

276 results

Filter options loading...
Top filers
Top filing types
Recent filing years
10-K
2001 FY
EX-10.11
PRPO Precipio Inc
24 Mar 02
Annual report
7:00pm
, including all exhibits hereto, as the same may be amended or otherwise modified from time to time. "CUSTOMER" shall mean a party with whom either TBIO … ) received from a Customer to which each party of this Agreement shall be entitled. The percentage amount of the Revenue Split to each party is further
10-Q
2002 Q3
PRPO Precipio Inc
11 Nov 02
Quarterly report
7:00pm
arrangement. Such recognition is based on receipt of an unconditional customer order and transfer of title and risk of ownership to the customer, typically … recognized $1.5 million in revenue in a transaction with a customer whereby the product sold, fulfilling the customers purchase order, was shipped
10-Q
2021 Q2
PRPO Precipio Inc
12 Aug 21
Quarterly report
4:07pm
our HSRR program, the customer can generate in-house testing revenues through reagent purchase contracts and economical lease-to-own rates instead … of sending out the same tests to large commercial reference laboratories. The HSRR customer also benefits from obtaining faster results, thus ultimately
10-Q
2021 Q1
PRPO Precipio Inc
14 May 21
Quarterly report
4:01pm
are referenced out as both the cost of equipment and the cost of the diagnostic reagents are prohibitive. By utilizing our HSRR program, the customer can … commercial reference laboratories. The HSRR customer also benefits from obtaining faster results, thus ultimately providing better patient care. During
10-Q
2021 Q3
PRPO Precipio Inc
12 Nov 21
Quarterly report
4:02pm
as both the cost of equipment and the cost of the diagnostic reagents are prohibitive. By utilizing our HSRR program, the customer can generate … reference laboratories. The HSRR customer also benefits from obtaining faster results, thus ultimately providing better patient care. During the first
10-K
eo3hqtwikw56oj809p1
30 Mar 06
Annual report
7:00pm
8-K
EX-99.1
4nl7z3q4p0j
28 Jul 21
Precipio Announces Preliminary Unaudited Q2-2021 Revenues of $2.3M
4:41pm
10-Q
r40ed4 naekuqw66
13 Aug 02
Quarterly report
8:00pm
8-K
EX-99.1
ngoim9l
26 Sep 19
Clinical Validations for IV-Cell™ and HemeScreen™ Completed
4:43pm
10-Q
two15bs ofo0u9
13 Nov 19
Quarterly report
4:33pm
10-K
2tt0y
1 Apr 07
Annual report
8:00pm
10-Q
fv1ow0ysldlxxgnsa73u
9 Aug 19
Quarterly report
2:55pm
10-Q
24e79en s9yjxienjlqw
13 May 02
Quarterly report
8:00pm
8-K
EX-99.1
v67fvhgz
29 Nov 10
Entry into a Material Definitive Agreement
7:00pm
10-Q
ghiz1ofuh u3k71rst7u
21 May 18
Quarterly report
3:16pm
10-K
xek3n9 2d9aeb7c
27 Mar 20
Annual report
3:47pm
10-K
EX-10.12
r1nkd t49sd1pfhpjr
24 Mar 02
Annual report
7:00pm
10-Q
4imtbpe8a ty3fbik6oi
13 May 09
Quarterly report
8:00pm
10-Q
swgsek3u5mch58phsjca
12 Aug 09
Quarterly report
8:00pm
10-Q
ik0kspoejujhljp98l5d
14 May 20
Quarterly report
4:05pm